John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company, will retire as president and CEO and from the company effective Dec. 31, 2016.
Grünenthal Group named Gabriel Baertschi to become the company’s new CEO as of Oct. 1, 2016.
Alicia Secor has been named president and CEO of Juniper Pharmaceuticals Inc., effective Aug. 1, 2016. Secor will also be appointed to the board of directors.
Dave Sheehan has joined ContextMedia:Health as chief marketing officer.
Grey Doyle is appointed CEO of Leading BioSciences Inc. Doyle, a long-standing member of Leading BioSciences’ executive management team and board of directors, previously served as chief operations officer and chief financial officer.
Glenn Nedwin, Ph.D., has become CEO, president, and member of the board of directors of Second Genome Inc.
John Lechleiter, the longtime CEO at Eli Lilly, will retire at the end of 2016. David Ricks, senior VP and president of Lilly Bio-Medicines, has been tapped as the successor.
Biogen reported Q2 profit that blew past Wall Street estimates; Chief Executive George Scangos will step down in the coming months once a successor is found.
Promotions demonstrate agency commitment to strategic thinking and client-focused delivery excellence July 20, 2016, PHILADELPHIA, Penn. — Razorfish Health, a uniquely integrated health marketing agency, announces the promotion of three individuals on the Account Management team. Lisa Turzio has been promoted to SVP, Group Account Director, Sarah Bast to VP, Group Account Director and […]
Omnicom Health Group announced that it is creating DDB Health, a dedicated, integrated healthcare network combining several U.S. and European professional healthcare agencies.